Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BCSF | 8-K | mixed | 5/10 | BCSF reported Q2 2026 net investment income (NII) of $0.44 per share, beating the $0.42 consensus and up from $0.42 in Q | Aug 10, 2026 |
| HLIO | 8-K | bullish | 7/10 | Helios Technologies reported Q2 2026 adjusted diluted EPS of $0.88, a 10% beat versus consensus of $0.80, on revenue of | Aug 10, 2026 |
| NOTE | 8-K | bearish | 7/10 | FiscalNote reported Q2 2026 revenue of $19.6M, in line with guidance, but GAAP EPS of -$1.06 massively missed consensus | Aug 10, 2026 |
| TONX | 8-K | mixed | 5/10 | TON Strategy Co (TONX) terminated its Advisory Services Agreement with Kingsway Capital Partners, a related party contro | Aug 10, 2026 |
| AL | 8-K | bearish | 6/10 | Sumisho Air Lease reported Q2 2026 Non-GAAP Combined total revenues of $641.1M, down 12.4% YoY, and net income attributa | Aug 10, 2026 |
| GAIA | 8-K | bearish | 5/10 | Gaia reported Q2 2026 revenue of $23.3M, down 5% YoY and missing consensus of $24.6M, as the company's strategic shift t | Aug 10, 2026 |
| BNGO | 8-K | mixed | 5/10 | Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31% co | Aug 10, 2026 |
| GUTS | 8-K | neutral | 4/10 | Fractyl Health reported Q2 2026 financial results with a net loss of $25.5M, improved from a $27.9M loss in Q2 2025, dri | Aug 10, 2026 |
| SPWR | 8-K | bearish | 6/10 | SunPower Inc. entered into a simple agreement for future equity (SAFE) with an institutional investor for $3,500,000. Th | Aug 10, 2026 |
| KOPN | 8-K | bearish | 5/10 | Kopin reported Q2 2026 revenue of $10.6M (flat YoY vs $10.5M) and a net loss of $0.9M ($0.00 EPS), improving from a $5.2 | Aug 10, 2026 |
| EVC | 8-K | neutral | 4/10 | Entravision reported Q2 2026 results with consolidated revenue up 126% YoY to $227.9M, driven by a 230% surge in the Adv | Aug 10, 2026 |
| ENTA | 8-K | bullish | 7/10 | Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate | Aug 10, 2026 |
| VERA | 8-K | neutral | 5/10 | Vera Therapeutics reported Q2 2026 earnings: net loss of $109.5M ($1.52/share) vs. $76.5M ($1.20/share) in Q2 2025, with | Aug 10, 2026 |
| OLMA | 8-K | neutral | 5/10 | Olema Pharmaceuticals reported a Q2 2026 net loss of $63.2M, wider than the $43.8M loss in Q2 2025, driven by increased | Aug 10, 2026 |
| PFLT | 8-K | bearish | 6/10 | PennantPark Floating Rate Capital (PFLT) reported Q3 2026 Core NII of $0.26 per share, missing the $0.27 consensus by 3. | Aug 10, 2026 |
| JRVR | 8-K | mixed | 5/10 | James River reported Q2 2026 GAAP net income available to common shareholders of $4.4M, up 59% YoY, but adjusted net ope | Aug 10, 2026 |
| NIQ | 8-K | bullish | 7/10 | NIQ delivered a strong Q2 beat, exceeding revenue, Adjusted EBITDA, and Adjusted EPS guidance. Revenue grew 8.0% YoY (5. | Aug 10, 2026 |
| HPK | 8-K | bullish | 7/10 | HighPeak Energy reported a strong Q2 2026 earnings beat, swinging from a GAAP net loss of $127.4M in Q1 to net income of | Aug 10, 2026 |
| TCMD | 8-K | bullish | 6/10 | Tactile Systems Technology reported Q2 2026 results with total revenue of $85.7 million (up 9% YoY), net income of $7.8 | Aug 10, 2026 |
| SEPN | 8-K | neutral | 4/10 | Septerna reported Q2 2026 financial results with a net loss of $13.0M, narrower than the $24.8M loss in Q2 2025. Revenue | Aug 10, 2026 |
| PIII | 8-K | bullish | 7/10 | P3 Health Partners delivered a strong Q2 2026 earnings beat, reporting GAAP net income of $15.7 million vs a net loss of | Aug 10, 2026 |
| BBIO | 8-K | neutral | 5/10 | BridgeBio reported Q2 2026 revenue of $243.7M, more than doubling YoY, driven by $222.4M in Attruby sales. The company c | Aug 10, 2026 |
| MLAB | 8-K | neutral | 6/10 | Mesa Labs reported a modest 1.0% revenue increase to $60.1M for Q1 FY2027, returning to positive core organic growth (0. | Aug 10, 2026 |
| PPHC | 8-K | neutral | 5/10 | PPHC reported Q2 2026 revenue of $52.1M (+7.3% YoY), slightly above the $51.6M consensus estimate from 2 analysts. Howev | Aug 10, 2026 |
| RPD | 8-K | bearish | 7/10 | Rapid7 reported Q2 2026 revenue of $210.9M (-1.5% YoY), missing the $208.2M consensus by 1.3%. Non-GAAP EPS of $0.44 bea | Aug 10, 2026 |
| GCTK | 8-K | bearish | 6/10 | Glucotrack amended its ELOC agreement with White Lion Capital to issue 2,505,513 commitment shares upon registration eff | Aug 10, 2026 |
| AMRX | 8-K | mixed | 7/10 | Amneal completed its acquisition of Kashiv BioSciences on August 10, 2026, paying $375M in cash and issuing 28,942,098 s | Aug 10, 2026 |
| ALTI | 8-K | bearish | 7/10 | AlTi Global reported Q2 2026 revenue of $58M (+11% YoY) and a GAAP net loss of -$30.8M from continuing operations, prima | Aug 10, 2026 |
| NGS | 8-K | bullish | 7/10 | NGS reported Q2 2026 rental revenue of $49.4M (+24.9% YoY) and adjusted EBITDA of $25.1M (+27.4% YoY), with record horse | Aug 10, 2026 |
| COCH | 8-K | neutral | 4/10 | Envoy Medical reported Q2 2026 results with a slim net revenue of $51K (down from $78K YoY), a net loss attributable to | Aug 10, 2026 |